

Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Horner Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Ir Michael V. Messinger Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowit
Peter A. Jackman
Jeffrey S. Weaver
Brian J. Del Buono
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht

Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longsworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Matthew E. Kelley
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Young Tang

Christopher J. Walsh W. Blake Coblentz+ James J. Pohl* John T. Haran Mark W. Rygiel Kevin W. McCabe

Registered Patent Agents-Karen R. Markowicz Matthew J. Dowd Katrina Yujian Pei Quach ` Bryan L. Skelton Robert A. Schwartzman Victoria S. Rutherford Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse Liliana Di Nola-Baron Peter A. Socarras Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie

*Admitted only in Maryland *Admitted only in Virginia *Practice Limited to Federal Agencies

December 4, 2006

WRITER'S DIRECT NUMBER: (202) 772-8858 INTERNET ADDRESS: JHEIDER@SKGF.COM

Mail Stop AF

Art Unit: 1635

Examiner: Schnizer, R.A. Confirmation No.: 3181

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/725,015; Filed: December 2, 2003

For: Method for Producing Sterile Polynucleotide Based Medicaments

Inventors: GEALL et al.

Our Ref: 1530.0610001/EKS/J-H

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Amendment and Reply Under 37 C.F.R. § 1.116; and
- 2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

Commissioner for Patents December 4, 2006 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Julie A. Heider

Agent for Applicants Registration No. 54,161

EKS/J-H/awt Enclosures

614712_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GEALL et al.

Appl. No.: 10/725,015

Filed: December 2, 2003

For: Method for Producing Sterile

Polynucleotide Based Medicaments

Confirmation No.: 3181

Art Unit: 1635

Examiner: Schnizer, R. A.

Atty. Docket: 1530.0610001/EKS/J-H

Amendment and Reply Under 37 C.F.R. § 1.116

Mail Stop AF

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated **September 6, 2006**, (PTO Prosecution File Wrapper Paper No. 20060821), Applicants submit the following Amendment and Remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks and Arguments begin on page 6 of this paper.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.